A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 4, 2004, Pages 290-295

  Scheiman, James M ^a,g   Cryer, Byron ^b   Kimmey, Michael B ^c   Rothstein, Richard I ^d   Riff, Dennis S ^e   Wolfe, Michael M ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DARTMOUTH COLLEGE   (United States)

^e Associated Gastroenterology   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adverse event; AE; CI; Confidence interval; COX 2; Cyclooxygenase isoenzyme 2; FDA; Gastrointestinal; GI; Nonsteroidal anti inflammatory drug; NSAID; OTC; Over the counter; U.S. Food and Drug Administration

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; ENDOSCOPY; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAXIMUM PERMISSIBLE DOSE; NORMAL HUMAN; POSTOPERATIVE COMPLICATION; PRESCRIPTION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; UPPER GASTROINTESTINAL MUCOSAL INJURY; UPPER GASTROINTESTINAL TRACT;

ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUGS, NON-PRESCRIPTION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HUMANS; IBUPROFEN; INTESTINAL MUCOSA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAPROXEN; PROBABILITY; PYRAZOLES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SULFONAMIDES;

EID: 1842531997     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00057-6     Document Type: Article

References (18)

1. Doyle G., Furey S., Berlin R., Cooper S., Jayawardena S., Ashraf E., Baird L. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter doses. Aliment Pharmacol Ther. 13:1999;897-906.
2. Lanza F., Royer G., Nelson R. An endoscopic evaluation of the effects of nonsteroidal anti-inflammatory drugs on the gastric mucosa. Gastrointest Endosc. 21:1975;103-105.
3. Strom B.L., Schinnar R., Bilker W.B., Feldman H., Farrar J.T., Carson J.L. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen. Arch Intern Med. 157:1997;2626-2631.
4. Lewis S.C., Langman M.J., Laporte J.R., Matthews J.N., Rawlins M.D., Wiholm B.E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding a meta-analysis based on individual patient data. Br J Clin Pharmacol. 54:2002;320-326.
5. Ashraf E., Cooper S., Marinucci L., Doyle G., Berlin R. GI safety of a non-selective NSAID vs a COX-2 inhibitor equivalency of ibuprofen and celecoxib in an OTC setting. Am J Gastroenterol. 97:(suppl):2002;S45. (abstr).
6. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 340:1999;1888-1899.
7. Scheiman J.M. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 69:(suppl):2002;SI40-SI46.
8. Tudor G., Koch G.G. Review of nonparametric methods for the analysis of crossover studies. Stat Methods Med Res. 3:1994;345-381.
9. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A., Quan H., Bolognese J., Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on patients with osteoarthritis. Arthritis Rheum. 43:2000;370-377.
10. Deeks J., Smith L., Bradley M. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis systematic review of randomized controlled trails. BMJ. 325:2002;619-623.
11. Graham D.Y., Smith J.L., Spjut H.J., Torres E. Gastric adaptation studies in humans during continuous aspirin administration. Gastroenterology. 95:1988;327-333.
12. Hernandez S., Rodriguez L.A.G. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med. 160:2000;2093-2099.
13. Laine L., Sloane R., Ferretti M., Cominelli F. A randomized, double-blind comparison of placbo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 42:1995;428-433.
14. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H., Bolognese J. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2 - specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology. 117:1999;776-783.
15. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 343:2000;1520-1528.
16. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class Study: a randomized controlled trial. JAMA. 284:2000;1247-1255.
17. Watson D.J., Harper S.E., Peng-Liang Z., Quan H., Bolognese J.A., Simon T.J. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor refecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 160:2000;2998-3003.
18. Jones R.H. Gastrointestinal side-effects of NSAIDs in the community. Br J Clin Practice. 49:1995;67-70.